Pre-Open Stock Movers 06/09: (AEMD) (WISH) (SLDB) Higher; (ODNS) (CPB) (CMTL) Lower (more...)

Aethlon Medical (AEMD) Announced a Direct 1.4M Share Offering at $9/sh

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a registered direct offering of 1,380,555 shares of its common stock, at a purchase price per share of $9.00, priced at-the-market under Nasdaq rules.

The closing of the offering is expected to occur on or about June 14, 2021, subject to the satisfaction of... More

Morgan Stanley Discontinues Coverage on Lordstown Motors (RIDE)

Morgan Stanley Discontinues Coverage on Lordstown Motors (NASDAQ: RIDE). The prior rating was Underperform, with an $8 price target.

Analyst Adam Jonas comments "We remove our Underweight rating on RIDE as we believe the market may be underestimating the economic, strategic, political and... More

Clarivate (CLVT) Prices 38.46M Share Common Offering at $26/Sh; Announces Concurrent 12.5M Convertible Preferred Share Offering

Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today the pricing of concurrent offerings of 38,461,538 ordinary shares at a price to the public of $26.00 per share, of which 28,846,154 ordinary shares are being offered by Clarivate and 9,615,384 ordinary shares are being offered by certain existing shareholders (the "Ordinary Share Offering"), and 12,500,000 5.25% Series A Mandatory Convertible preferred shares (the "convertible preferred shares") at a price to the public of $100 per share (the "Convertible Preferred Share Offering," and together with the Ordinary Share Offering, the "Offerings").... More

Aclaris Therapeutics (ACRS) Prices 7.042M Share Common Offering at $17.75/Sh

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares of its common stock at a price to the public of $17.75 per share. In... More

Clover Health (CLOV) Quickly Pares Gain, Still Up 10%

Clover Health (NASDAQ: CLOV) Quickly Pares Gain, Still Up 10%